ESC Congress 2022 (Photo by Kyle LaHucik)
August 27, 2022 11:03 AM EDTUpdated August 29, 05:10 PM
R&D
Pharma

#ESC22: ‘Anx­ious for more ev­i­dence’: As­traZeneca touts DE­LIV­ER da­ta in bid to ex­pand Farx­i­ga’s heart fail­ure la­bel 

Kyle LaHucik

Senior Reporter

BARCELONA — Three and a half months af­ter teas­ing a topline win for its heart fail­ure and type 2 di­a­betes med Farx­i­ga, As­traZeneca laid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times